Radafaxine
Radafaxine (pronunciation: rah-duh-fax-een) is a pharmaceutical drug that was developed by GlaxoSmithKline for the treatment of depression and fatigue. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and is chemically related to bupropion.
Etymology
The term "Radafaxine" is a coined name, with no specific etymology. It is a common practice in the pharmaceutical industry to create unique, easily pronounceable names for new drugs.
Pharmacology
Radafaxine acts by inhibiting the reuptake of the neurotransmitters norepinephrine and dopamine, thereby increasing their availability in the brain. This mechanism of action is similar to that of other NDRIs, such as bupropion.
Clinical Use
Radafaxine was investigated for use in the treatment of depression and fatigue, including fatigue associated with multiple sclerosis. However, development was discontinued in the late-stage clinical trials due to lack of efficacy.
Related Terms
- Pharmaceutical drug
- GlaxoSmithKline
- Depression
- Fatigue
- Norepinephrine-dopamine reuptake inhibitor
- Bupropion
- Norepinephrine
- Dopamine
- Multiple sclerosis
External links
- Medical encyclopedia article on Radafaxine
- Wikipedia's article - Radafaxine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski